Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history studyAarhus University Hospital, Aarhus, Denmark.
Zealand University Hospital, Roskilde, Denmark.
University of Copenhagen, Copenhagen, Denmark.
Cardiovascular Research Foundation, New York, NY, USA.
Cardiovascular Research Foundation, New York, NY, USA.
Cardiovascular Research Foundation, New York, NY, USA.
Cardiovascular Research Foundation, New York, NY, USA.
Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
St Olavs Hospital, Trondheim University Hospital, Norway.
Stavanger University Hospital, Stavanger, Norway.
Odense University Hospital, Odense, Denmark.
University of Bergen, Bergen, Norway.
Haukeland University Hospital, Bergen, Norway.
Department of Cardiology,Sahlgrenska University Hospital, Gothenburg, Sweden.
Uppsala University and Uppsala Clinical Research Center, Uppsala, Sweden.
Uppsala University and Uppsala Clinical Research Center, Uppsala, Sweden.
NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY, USA; Cardiovascular Research Foundation, New York, NY, USA.
Brigham and Women's Hospital, Boston, MA, USA.
Cardiovascular Research Foundation, New York, NY, USA; The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Show others and affiliations
2021 (English)In: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 397, no 10278, p. 985-995Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: Near-infrared spectroscopy (NIRS) and intravascular ultrasound are promising imaging modalities to identify non-obstructive plaques likely to cause coronary-related events. We aimed to assess whether combined NIRS and intravascular ultrasound can identify high-risk plaques and patients that are at risk for future major adverse cardiac events (MACEs).
METHODS: PROSPECT II is an investigator-sponsored, multicentre, prospective natural history study done at 14 university hospitals and two community hospitals in Denmark, Norway, and Sweden. We recruited patients of any age with recent (within past 4 weeks) myocardial infarction. After treatment of all flow-limiting coronary lesions, three-vessel imaging was done with a combined NIRS and intravascular ultrasound catheter. Untreated lesions (also known as non-culprit lesions) were identified by intravascular ultrasound and their lipid content was assessed by NIRS. The primary outcome was the covariate-adjusted rate of MACEs (the composite of cardiac death, myocardial infarction, unstable angina, or progressive angina) arising from untreated non-culprit lesions during follow-up. The relations between plaques with high lipid content, large plaque burden, and small lumen areas and patient-level and lesion-level events were determined. This trial is registered with ClinicalTrials.gov, NCT02171065.
FINDINGS: Between June 10, 2014, and Dec 20, 2017, 3629 non-culprit lesions were characterised in 898 patients (153 [17%] women, 745 [83%] men; median age 63 [IQR 55-70] years). Median follow-up was 3·7 (IQR 3·0-4·4) years. Adverse events within 4 years occurred in 112 (13·2%, 95% CI 11·0-15·6) of 898 patients, with 66 (8·0%, 95% CI 6·2-10·0) arising from 78 untreated non-culprit lesions (mean baseline angiographic diameter stenosis 46·9% [SD 15·9]). Highly lipidic lesions (851 [24%] of 3500 lesions, present in 520 [59%] of 884 patients) were an independent predictor of patient-level non-culprit lesion-related MACEs (adjusted odds ratio 2·27, 95% CI 1·25-4·13) and non-culprit lesion-specific MACEs (7·83, 4·12-14·89). Large plaque burden (787 [22%] of 3629 lesions, present in 530 [59%] of 898 patients) was also an independent predictor of non-culprit lesion-related MACEs. Lesions with both large plaque burden by intravascular ultrasound and large lipid-rich cores by NIRS had a 4-year non-culprit lesion-related MACE rate of 7·0% (95% CI 4·0-10·0). Patients in whom one or more such lesions were identified had a 4-year non-culprit lesion-related MACE rate of 13·2% (95% CI 9·4-17·6).
INTERPRETATION: Combined NIRS and intravascular ultrasound detects angiographically non-obstructive lesions with a high lipid content and large plaque burden that are at increased risk for future adverse cardiac outcomes.
Place, publisher, year, edition, pages
Elsevier, 2021. Vol. 397, no 10278, p. 985-995
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:oru:diva-90454DOI: 10.1016/S0140-6736(21)00249-XISI: 000627814200027PubMedID: 33714389Scopus ID: 2-s2.0-85102286136OAI: oai:DiVA.org:oru-90454DiVA, id: diva2:1537596
Note
Funding Agencies:
Abbott Laboratories
Infraredx
The Medicines Company
2021-03-162021-03-162025-02-10Bibliographically approved